Archive


Category: Avillion

  • AstraZeneca, Avillion ‘first-in-class’ combination inhaler shines in Phase 3 trial

    An albuterol/budesonide fixed-dose combination rescue medication has been shown to reduce severe exacerbations in patients with asthma for the first time, according to positive Phase 3 trial results announced by AstraZeneca and Avillion. Asthma affects as many as 339 million adults and children around the world. Regardless of severity, the condition means that these patients […]

  • Avillion/Merck psoriasis nanobody hits the mark in phase 2

    UK biotech Avillion has reported positive mid-stage results with chronic psoriasis drug sonelokimab, which it is developing with Merck KGaA as an alternative to drugs like Novartis’ Cosentyx.  The IL-17A and IL-17F inhibitor hit all its objectives in the phase 2 trial, which has now been published in The Lancet, and showed that it was […]